Evidence map›Paper›PMID 26558012›Full record

ReviewArab journal of urology2012

Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway.

Ramy F Youssef, Nicholas G Cost, Oussama M Darwish, Vitaly Margulis

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arab journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ramy F YoussefDivision of Urologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Nicholas G CostDivision of Urologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Oussama M DarwishDivision of Urologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Vitaly MargulisDivision of Urologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
The University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIncreased knowledge about the molecular pathways involved in tumorigenesis has led to the discovery of new prognostic molecular markers and development of novel targeted therapies for renal cell carcinoma (RCC). In this review we describe the prognostic markers of RCC and highlight the areas of recent discovery with a focus on the mammalian target of rapamycin (mTOR) pathway.

methodsWe reviewed previous reports, using PubMed with the search terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 'mammalian target of rapamycin pathway' published in the last two decades. We created a library of 100 references and focused on presenting the recent advances in the field.

resultsGrowing evidence suggests that mTOR deregulation is associated with many types of human cancer, including RCC. Consequently, temsirolimus and everolimus, which target mTOR, are approved for treating advanced RCC. There is a demand to integrate clinical, pathological and molecular markers into accurate prognostic models to provide patients with the most personalised cancer care possible.

conclusionsThe mTOR pathway is highly implicated in RCC tumorigenesis and progression, and its constituents might represent a promising prognostic tool and target for treating RCC. Combining newly discovered molecular markers with classic clinicopathological prognostics might potentially improve the management of RCC.

Indexed as

4E-BP1, eukaryotic initiation factor-binding protein-1CA-9, carbonic anhydrase 9HIF, hypoxia inducible factorIRS-1, insulin receptor substrate-1LDH, lactate dehydrogenaseMolecular markersmTORmTOR, mammalian target of rapamycinPI3k, phosphatidylinositol 3-kinasePrognosticRenal cell carcinomaS6K1, S6 kinase 1TKR, tyrosine kinase receptorTSC, tuberous sclerosis complexVEGF, vascular endothelial growth factorVHL, von Hippel-Lindau

Identifiers

PMID26558012
PMCPMC4442886
OpenAlexW1981736211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.